afabicin (Debio 1450)
afabicin (Debio 1450), is a new antibiotic benefiting from both oral and IV formulations. It is a highly potent, staphylococcus-selective antibiotic with a low propensity to emergence of resistance. This first-in-class FabI inhibitor retains its activity on staphylococci strains resistant to antibiotics currently in clinical use including beta lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, will now be studied in Bone & Joint infections (BJIs) caused by staphylococci.
January 10, 2017
Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
October 25, 2016
Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450
April 23, 2015
Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections